Gilead pauses access to experimental Covid-19 drug due to ‘overwhelming demand’
FEATURECHINA VIA AP
The company said “enrollment in clinical trials is the primary way to access remdesivir to generate critical data" on appropriate use of the drug.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario